Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /mnt/web018/d0/98/57269998/htdocs/WordPress_05/wp-content/plugins/revslider/includes/operations.class.php on line 2758 Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /mnt/web018/d0/98/57269998/htdocs/WordPress_05/wp-content/plugins/revslider/includes/operations.class.php on line 2762 Warning: "continue" targeting switch is equivalent to "break". Did you mean to use "continue 2"? in /mnt/web018/d0/98/57269998/htdocs/WordPress_05/wp-content/plugins/revslider/includes/output.class.php on line 3689 Science – PerioPreventionCenter


Thirty years of basic and clinical research, with more than 212 publications in the field of dentistry and approximately 900 publications in the field of medicine, clearly demonstrate the benefits and advantages of aMMP-8 biomarker technology for the patient.

The medical statements presented on this website are founded on evidence-based science. Therefore, you will find text passages, text sources and citations by renowned scientists, which we have summarized here for you.

Using the proven superior sensitivity and specificity of our aMMP-8 technologies, we measure the enzyme and dynamic process of active periodontal degeneration (APD). There are numerous associated topic-related studies on this, for which we would like to give you an overview here.

An overview of the performance data:

All in vitro diagnostic and a biomarker technology products are DIN ISO certified, CE registered and patented worldwide.

All products are developed in cooperation with scientific institutes and universities in Germany and produced according to the highest quality standards for our supplier company Dentognostics.

Dentognostics has been certified to DIN ISO EN 13485:2010 since 2004.

Link to the PubMed page with more than 240 publications on aMMP-8

Link to the science page of the PerioPrevention network website

Interdisziplinäre Konsensuskonferenz für Medizin & Zahnheilkunde 2020: Schließung eines Bündnisses zur Prävention oraler und systemischer Erkrankungen

Summary of the scientific communication of the DGP and DGZMK

Here below, you can read a brief summary of the Scientific Communication of the German Society for Periodontology (DGP) and the German Society of Dental, Oral and Maxillofacial Surgery (DGZMK) on “Periodontitis diagnostics with the inflammatory marker MMP-8”:

DG Paro and DGZMK evaluate aMMP-8 test for periodontitis diagnostics

In a joint scientific communication, the German Society for Periodontics (DG PARO) and Society for Oral and Maxillofacial Surgery (DGZMK) evaluate the inflammatory marker MMP-8 for periodontitis diagnostics. The 18-page opinion on the MMP-8 test procedure provides the scientific foundation for the use of the PerioSafe®PRO oral health test from Dentognostics in daily practice.


Matrix metalloproteinase-8 (MMP-8) is an endogenous enzyme induced by periodontal

inflammation in gingival tissue. In its activated form (aMMP-8), it is responsible for the breakdown of the collagen fibers of the periodontium in periodontal disease and

peri-implantitis. For the DG PARO and DGZMK, “of all possible tests for the

inflammatory-induced expression of matrix metalloproteinases…the test for MMP-8 is a particular favorite for the diagnosis of periodontitis.

The detection of aMMP-8 is possible in the sulcus fluid, saliva or mouthwash. Dentognostics’ PerioSafe® PRO Oral Health Test can detect elevated levels of aMMP-8 in a mouthwash solution. The advantage over other methods: the qualitative chairside test provides indications of the risk of progressive destructive disease of the periodontium, which may become apparent only weeks or months later using a probe or X-ray. That means that

PerioSafe® acts as an ”early warning system“.


The authors cite follow-up monitoring as a potential application for the PerioSafe® test : “The treatment success from e.g. scaling and root planing (SRP) can be tracked using MMP-8 to distinguish responders from nonresponders to the treatment.” Therefore, it makes sense to use PerioSafe® PRO before every professional tooth cleaning once or twice a year as a screening for hidden tissue degradation processes for periodontitis risk diagnosis and as part of the adjunctive periodontal therapy at least once a year as part of regular prophylaxis and recall.


The DG PARO and DGZMK emphasize in their remarks that the simplicity of performing this test is impressive. In fact, a medical professional only needs a few minutes for the PerioSafe® PRO test. The pure “hands-on” time is about three minutes – including wait time to read the test result, just over ten minutes elapse. Consequently, the test is also delegable, e.g. to the dental hygienist or a healthcare professional.


Another proposal by the authors Eickholz and Meisel for a “beneficial application: …to introduce the test when no dentist is available. This brings to mind medical practices specializing in those systemic diseases which clearly have associations with periodontitis, e.g. diabetes or obesity.” Numerous studies have shown a correlation between periodontal and systemic disease. Especially for chronically ill individuals who suffer from diabetes, cardiovascular diseases, COPD or rheumatoid arthritis, as well as for women who wish to conceive, the early detection and treatement of hidden oral inflammation is of great importance. Internal medicine specialists and gynecologists who screen their patients with PerioSafe® PRO will, if they find a positive result, refer them to a periodontist or periodontics specialist. Therefore, the PerioSafe® PRO Test is an important link for interdisciplinary communication between physicians and dentists.



The scientific opinion was published in November 2016. The authors are pharmacologist Prof. Dr. med. Peter Meisel from the Center for Oral and Maxillofacial Surgery of the University of Greifswald and Prof. Dr. med. Peter Eickholz, Director of the Polyclinic for Periodontology at the Center for Oral and Maxillofacial Surgery at the Johann Wolfgang Goethe University Frankfurt.

Editor’s note: The scientific communication dates from 2016. At that time, ORALyzer technology was not yet available for digital quantification of aMMP-8 results. As of 6/2017, samples can be evaluated directly in the patient. Thus, the assessment of responders/nonresponders is now cost-effective. Individual implants or teeth can also be analyzed individually. Consequently, Dentognostics has fulfilled an important requirement of the authors of the scientific communication.

Below, you can read the complete scientific communication “Periodontitis diagnostics with the inflammatory marker MMP-8” by authors Prof. Dr. med. Peter Meisel of the University Medical Center Greifswald and Prof. Dr. med. Peter Eickholz of the Polyclinic for Periodontology of the Johann Wolfgang Goethe University Frankfurt

The adjacent summary by Prof. dr. Eickholz interprets the application of the test in interdisciplinary diagnostics.

Below, you can read the complete scientific presentation “Oral biomarker diagnostics for early detection of periodontitis and interdisciplinary risk analysis” by the authors

Prof. Dr. Ulrich Schlagenhauf

Prof. Timo Sorsa PhD

OA PD Dr. med. Heinrich Körtke

PD Dr. Lutz Netuschil

Maria Emanuel Ryan, D.D.S., Ph.D.

Laurenz Meyer, CDU General Secretary ret.

Dr. med. dent., oec. med. Björn Eggert

Cordula Hordt, Orthodontist